Hopeful1976
Senior Member
- Messages
- 345
Just received this email detailing latest info:
Dear Friends of Cortene, We are writing to let you know we have just completed our clinical trail in ME/CFS earlier this week. As you may already be aware, the trial was based upon our theory that a single receptor was up-regulated in the brains of ME/CFS patients. It proposed a novel therapeutic approach, in which a short exposure to a novel peptide (CT38) was intended to down-regulatethe receptor, leading to symptom improvement. Our small (n=14) trial utilized 3 treatments of CT38, at 4 different dose-levels (no placebo). While we understand you are anxious to hear about our observations, it would be premature to share these until the data has been thoroughly reviewed and analyzed. We anticipate it will take 1-2 months to complete our analysis and write up our findings. That said, we have found the data encouraging and believe they support moving toward a randomized, double blind, placebo controlled trial. This will require significant funding and we are currently pursuing various channels to support continued development. We look forward to sharing more details soon and thank you for your continued support and patience. Regards, Michael
Dear Friends of Cortene, We are writing to let you know we have just completed our clinical trail in ME/CFS earlier this week. As you may already be aware, the trial was based upon our theory that a single receptor was up-regulated in the brains of ME/CFS patients. It proposed a novel therapeutic approach, in which a short exposure to a novel peptide (CT38) was intended to down-regulatethe receptor, leading to symptom improvement. Our small (n=14) trial utilized 3 treatments of CT38, at 4 different dose-levels (no placebo). While we understand you are anxious to hear about our observations, it would be premature to share these until the data has been thoroughly reviewed and analyzed. We anticipate it will take 1-2 months to complete our analysis and write up our findings. That said, we have found the data encouraging and believe they support moving toward a randomized, double blind, placebo controlled trial. This will require significant funding and we are currently pursuing various channels to support continued development. We look forward to sharing more details soon and thank you for your continued support and patience. Regards, Michael